Neumora Therapeutics, Inc. (NMRA)
0.5253
+0.03
(+5.08%)
USD |
NASDAQ |
Oct 05, 16:00
0.525
0.00 (0.00%)
After-Hours: 06:40
Neumora Therapeutics Enterprise Value : 34.57M for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 34.57M |
| October 02, 2026 | 29.82M |
| October 01, 2026 | 39.19M |
| September 30, 2026 | 47.82M |
| September 29, 2026 | 63.03M |
| September 28, 2026 | 65.68M |
| September 25, 2026 | 63.03M |
| September 24, 2026 | 67.79M |
| September 23, 2026 | 73.06M |
| September 22, 2026 | 81.88M |
| September 21, 2026 | 65.68M |
| September 18, 2026 | 72.82M |
| September 17, 2026 | 76.56M |
| September 16, 2026 | 80.89M |
| September 15, 2026 | 91.75M |
| September 14, 2026 | 123.16M |
| September 11, 2026 | 130.74M |
| September 10, 2026 | 149.43M |
| September 09, 2026 | 160.64M |
| September 08, 2026 | 169.98M |
| September 04, 2026 | 181.19M |
| September 03, 2026 | 188.67M |
| September 02, 2026 | 194.27M |
| September 01, 2026 | 184.93M |
| August 31, 2026 | 184.93M |
| Date | Value |
|---|---|
| August 28, 2026 | 196.14M |
| August 27, 2026 | 212.96M |
| August 26, 2026 | 227.91M |
| August 25, 2026 | 216.69M |
| August 24, 2026 | 221.37M |
| August 21, 2026 | 240.99M |
| August 20, 2026 | 219.50M |
| August 19, 2026 | 242.85M |
| August 18, 2026 | 242.85M |
| August 17, 2026 | 220.43M |
| August 14, 2026 | 235.38M |
| August 13, 2026 | 259.67M |
| August 12, 2026 | 255.93M |
| August 11, 2026 | 254.06M |
| August 10, 2026 | 239.12M |
| August 07, 2026 | 240.99M |
| August 06, 2026 | 242.85M |
| August 05, 2026 | 237.25M |
| August 04, 2026 | 235.38M |
| August 03, 2026 | 242.85M |
| July 31, 2026 | 237.25M |
| July 30, 2026 | 244.72M |
| July 29, 2026 | 244.72M |
| July 28, 2026 | 250.33M |
| July 27, 2026 | 246.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioAge Labs, Inc. | -24.77M |
| ANI Pharmaceuticals, Inc. | 1.902B |
| Corcept Therapeutics, Inc. | 12.87B |
| Veru, Inc. | 20.37M |
| Johnson & Johnson | 637.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.08M |
| Total Expenses (Quarterly) | 43.08M |
| EPS Diluted (Quarterly) | -0.2327 |
| Earnings Yield | -234.8% |
| Normalized Earnings Yield | -230.67 |